Recent developments in chimeric NSAIDs as anticancer agents: Teaching an old dog a new trick

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 15, 2016, Pages 1201-1218

  Suthar, Sharad Kumar ^a   Sharma, Manu ^b  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

Author keywords

Cancer; COX; Inflammation; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CANCER GROWTH FACTOR; CELECOXIB; CHIMERIC PROTEIN; CISPLATIN; DICLOFENAC; ETORICOXIB; FIBROBLAST GROWTH FACTOR; FLURBIPROFEN; HYDROGEN SULFIDE; I KAPPA B; I KAPPA B KINASE ALPHA; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; NAPROXEN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PROSTAGLANDIN SYNTHASE; RIBOFLAVIN; ROFECOXIB; SULINDAC; VALDECOXIB; VASCULOTROPIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN A;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER RECURRENCE; CYTOTOXICITY; HUMAN; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR RESISTANCE; UPREGULATION; ANIMAL; CHEMISTRY; COMPLICATION; DRUG DEVELOPMENT; IMMUNOLOGY; INFLAMMATION; NEOPLASMS; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; INFLAMMATION; NEOPLASMS; NF-KAPPA B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84989246709     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666160428111419     Document Type: Review

References (89)

1. World Health Organization. Cancer. http://www.who.int/cancer/en/ (Accessed June 13, 2014).
2. International Agency for Research on Cancer. Cancer Stats Cancer Worldwide. http://publications.cancerresearchuk.org/downloads/product/CS_C S_WORLD.pdf (Accessed June 13, 2014).
3. American Cancer Society. Cancer Facts & Figures 2012. http://www.cancer.org/ acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-031941.pdf (Accessed April 29, 2014).
4. National Institute of Health and Family Welfare. National Cancer Control Programme. http://nihfw.nic.in/ndc-nihfw/html/Programmes/ National Cancer Control Programme.htm (Accessed March 10, 2014).
5. Suthar, S.K.; Jaiswal, V.; Lohan, S.; Bansal, S.; Chaudhary, A.; Tiwari, A.; Alex, A.T.; Joesph, A. Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening. Eur. J. Med. Chem., 2013, 63, 589-602.
6. Rayburn, E.R.; Ezell, S.J.; Zhang, R. Anti-inflammatory agents for cancer therapy. Mol. Cell. Pharmacol., 2009, 1, 29-43.
7. Arias, J.I.; Aller, M.A.; Arias, J. Cancer cell: Using inflammation to invade the host. Mol. Cancer, 2007, 6, 29.
8. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420, 860-867.
9. Lu, Y.; Cai, Z.; Galson, D.L.; Xiao, G.; Liu, Y.; George, D.E.; Melhem, M.F.; Yao, Z.; Zhang, J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate, 2006, 66, 1311-1318.
10. Van Waes, C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin. Cancer Res., 2007, 13, 1076-1082.
11. Rose-John, S.; Waetzig, G.H.; Scheller, J.; Grötzinger, J.; Seegert, D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert. Opin. Ther. Targets, 2007, 11, 613-624.
12. Galliera, E.; Corsi, M.M.; Bonecchi, R.; Locati, M.; Mantovani, A. Chemokines as pharmacological targets. Mini. Rev. Med. Chem., 2008, 8, 638-646.
13. Knowles, M.A. Novel therapeutic targets in bladder cancer: Mutation and expression of FGF receptors. Future Oncol., 2008, 4, 71-83.
14. Wang, D.; Dubois, R.N. Prostaglandins and cancer. Gut, 2006, 55, 115-122.
15. Lee, J.M.; Yanagawa, J.; Peebles, K.A.; Sharma, S.; Mao, J.T.; Dubinett, S.M. Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment. Crit. Rev. Oncol. Hematol., 2008, 66, 208-217.
16. MEDIMOON. Difference between COX1 and COX2. http://medimoon.com/ 2013/05/difference-between-cox1-and-cox2/ (Accessed June 22, 2014)
17. Rao, P.N.P.; Knaus, E.E. Evolution of nonsteroidal antiinflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharmaceut. Sci., 2008, 11, 81s-110s.
18. Takada, Y.; Bhardwaj, A.; Potdar, P.; Aggarwal, B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene, 2004, 23, 9247-9258.
19. Zhang, G.; Tu, C.; Zhang, G.; Zhou, G.; Zheng, W. Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk. Res., 2000, 24, 385-392.
20. Maguire, A.R.; Plunkett, S.J.; Papot, S.; Clynes, M.; O’Connor, R.; Touhey, S. Synthesis of indomethacin analogues for evaluation as modulators of MRP activity. Bioorg. Med. Chem., 2001, 9, 745-762.
21. Gobec, S.; Brožič, P.; Rižner, T.L. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: New lead compounds for the development of anticancer agents. Bioorg. Med. Chem. Lett., 2005, 15, 5170-5175.
22. Su, B.; Chen, S. Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells. Bioorg. Med. Chem. Lett., 2009, 19, 6733-6735.
23. Schmeltzer, R.C.; Schmalenberg, K.E.; Uhrich, K.E. Synthesis and cytotoxicity of salicylate-based poly(anhydride esters). Biomacromolecules, 2005, 6, 359-367.
24. Congiu, C.; Cocco, M.T.; Lilliu, V.; Onnis, V. New potential anticancer agents based on the anthranilic acid scaffold: Synthesis and evaluation of biological activity. J. Med. Chem., 2005, 48, 8245-8252.
25. Banekovich, C.; Ott, I.; Koch, T.; Matuszczaka, B.; Gust, R. Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates. Bioorg. Med. Chem. Lett., 2007, 17, 683-687.
26. Barbarić, M.; Kralj, M.; Marjanović, M.; Husnjak, I.; Pavelić, K.; Filipović-Grčić, J.; Zorc, D.; Zorc B. Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. Eur. J. Med. Chem., 2007, 42, 20-29.
27. Romeiro, N.C.; Sant’Anna, C.M.; Lima, L.M.; Fraga, C.A.; Barreiro, E.J. NSAIDs revisited: Putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARγ). Eur. J. Med. Chem., 2008, 43, 1918-1925.
28. Bass, S.E.; Sienkiewicz, P.; MacDonald, C.J.; Cheng. R.Y.; Sparatore, A.; Del Soldato, P.; Roberts, D.D.; Moody, T.W.; Wink, D.A.; Yeh, G.C. Novel dithiolethione-modified nonsteroidal antiinflammatory drugs in human hepatoma HepG2 and Colon LS180 cells. Clin. Cancer Res., 2009, 15, 1964-1972.
29. Wittine, K.; Benci, K.; Rajić, Z.; Zorc, B.; Kralj, M.; Marjanović, M.; Pavelić, K.; De Clercq, E.; Andrei, G.; Snoeck, R.; Balzarini, J.; Mintas, M. The novel phosphoramidate derivatives of NSAID 3- hydroxypropylamides: Synthesis, cytostatic and antiviral activity evaluations. Eur. J. Med. Chem., 2009, 44, 143-151.
30. Zawidlak-Wegrzyńska, B.; Kawalec, M.; Bosek, I.; Łuczyk-Juzwa, M.; Adamus, G.; Rusin, A.; Filipczak, P.; Głowala-Kosińska, M.; Wolańska, K.; Krawczyk, Z.; Kurcok, P. Synthesis and antiproliferative properties of ibuprofen-oligo(3-hydroxybutyrate) conjugates. Eur. J. Med. Chem., 2010, 45, 1833-1842.
31. Fogli, S.; Banti, I.; Stefanelli, F.; Picchianti, L.; Digiacomo, M.; Macchia, M.; Breschi, M.C.; Lapucci, A. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. Eur. J. Med. Chem., 2010, 45, 5100-5107.
32. Kapadia, G.J.; Azuine, M.A.; Shigeta, Y.; Suzuki, N.; Tokuda, H. Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis. Bioorg. Med. Chem. Lett., 2010, 20, 2546-2548.
33. Desai, D.; Sinha, I.; Null, K.; Wolter, W.; Suckow, M.A.; King, T.; Amin, S.; Sinha, R. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells. Int. J. Cancer, 2010, 127, 230-238.
34. Liu, M.; Yuan, M.; Li, Z.; Cheng, Y.K.; Luo, H.B.; Hu, X. Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I. Bioorg. Med. Chem. Lett., 2011, 21, 4243-4247.
35. Su, Y.H.; Chiang, L.W.; Jeng, K.C.; Huang, H.L.; Chen, J.T.; Lin, W.J.; Huang, C.W.; Yu, C.S. Solution-phase parallel synthesis and screening of anti-tumor activities from fenbufen and ethacrynic acid libraries. Bioorg. Med. Chem. Lett., 2011, 21, 1320-1324.
36. Chennamaneni, S.; Zhong, B.; Lama, R.; Su, B. COX inhibitors Indomethacin and sulindac derivatives as antiproliferative agents: Synthesis, biological evaluation, and mechanism investigation. Eur. J. Med. Chem., 2012, 56, 17-29.
37. Rosenbaum, C.; Röhrs, S.; Müller, O.; Waldmann, H. Modulation of MRP-1-mediated multidrug resistance by indomethacin analogues. J. Med. Chem., 2005, 48, 1179-1187.
38. Bernardi, A.; Jacques-Silva, M.C.; Delgado-Cañedo, A.; Lenz, G.; Battastini, A.M. Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell lines. Eur. J. Pharmacol., 2006, 532, 214-222.
39. Lee, B.S.; Yoon, C.W.; Osipov, A.; Moghavem, N.; Nwachokor, D.; Amatya, R.; Na, R.; Pantoja, J.L.; Pham, M.D.; Black, K.L.; Yu, J.S. Nanoprodrugs of NSAIDs: Preparation and characterization of flufenamic acid nanoprodrugs. J. Drug. Deliv., 2011, 980720, 1-13.
40. Liedtke, A.J.; Crews, B.C.; Daniel, C.M.; Blobaum, A.L.; Kingsley, P.J.; Ghebreselasie, K.; Marnett, L.J. Cyclooxygenase-1- selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. J. Med. Chem., 2012, 55, 2287-2300.
41. Calvello, R.; Panaro, M.A.; Carbone, M.L.; Cianciulli, A.; Perrone, M.G.; Vitale, P.; Malerba, P.; Scilimati, A. Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPSstimulated N13 microglial cells. Pharmacol. Res., 2012, 65, 137-148.
42. Bocca, C.; Bozzo, F.; Miglietta, A. COX2 inhibitor NS398 reduces HT-29 cell invasiveness by modulating signaling pathways mediated by EGFR and HIF1-α. Anticancer Res., 2014, 34, 1793-1800.
43. Vaeteewoottacharn, K.; Mitchai, M.; Srikoon, P.; Hattori, S.; Kariya, R.; Matsuda, K.; Wongkham, S.; Okada, S. Potent reactive oxygen species-JNK-p38 activation by sodium salicylate potentiates death of primary effusion lymphoma cells. Anticancer Res., 2014, 34, 1865-1871.
44. Chen, L.; Wang, Z.G.; Aleshin, A.E.; Chen, F.; Chen, J.; Jiang, F.; Alitongbieke, G.; Zeng, Z.; Ma, Y.; Huang, M.; Zhou, H.; Cadwell, G.; Zheng, J.F.; Huang, P.Q.; Liddington, R.C.; Zhang, X.K.; Su, Y. Sulindac-derived RXRα modulators inhibit cancer cell growth by binding to a novel site. Chem. Biol., 2014, 21, 596-607.
45. Yeh, R.K.; Chen, J.; Williams, J.L.; Baluch, M.; Hundley, T.R.; Rosenbaum, R.E.; Kalala, S.; Traganos, F.; Benardini, F.; del Soldato, P.; Kashfi, K.; Rigas, B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: A general pharmacological property?. Biochem. Pharmacol., 2004, 67, 2197-2205.
46. Bézière, N.; Goossens, L.; Pommery, J.; Vezin, H.; Touati, N.; Hénichart, J.P.; Pommery, N. New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines. Bioorg. Med. Chem. Lett., 2008, 18, 4655-4657.
47. Stewart, G.D.; Nanda, J.; Brown, D.J.; Riddick, A.C.; Ross, J.A.; Habib, F.K. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int. J. Cancer, 2009, 124, 223-232.
48. Dunlap, T.; Piyankarage, S.C.; Wijewickrama, G.T.; Abdul-Hay, S.; Vanni, M.; Litosh, V.; Luo, J.; Thatcher, G.R. Quinone-induced activation of Keap1/Nrf2 signaling by aspirin prodrugs masquerading as nitric oxide. Chem. Res. Toxicol., 2012, 25, 2725-2736.
49. Chaudhary, S.C.; Singh, T.; Kapur, P.; Weng, Z.; Arumugam, A.; Elmets, C.A.; Kopelovich, L.; Athar, M. Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVBinduced photocarcinogenesis. Toxicol. Appl. Pharmacol., 2013, 268, 249-255.
50. Nicastro, H.L.; Grubbs, C.J.; Margaret Juliana, M.; Bode, A.M.; Kim, M.S.; Lu, Y.; You, M.; Milne, G.L. Boring, D.; Steele, V.E.; Lubet, R.A. Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. Cancer Prev. Res., 2014, 7, 246-254.
51. Cheng, H.; Mollica, M.Y.; Lee, S.H.; Wang, L.; Velázquez-Martínez, C.A.; Wu, S. Effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NONO-NSAIDs) on melanoma cell adhesion. Toxicol. Appl. Pharmacol., 2012, 264, 161-166.
52. Basudhar, D.; Bharadwaj, G.; Cheng, R.Y.; Jain, S.; Shi, S.; Heinecke, J.L.; Holland, R.J.; Ridnour, L.A.; Caceres, V.M.; Spadari-Bratfisch, R.C.; Paolocci, N.; Velázquez-Martínez, C.A.; Wink, D.A.; Miranda, K.M. Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives. J. Med. Chem., 2013, 56, 7804-7820.
53. Chattopadhyay, M.; Kodela, R.; Nath, N.; Dastagirzada, Y.M.; Velázquez-Martínez, C.A.; Boring, D.; Kashfi, K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem. Pharmacol., 2012, 83, 715-722.
54. Chattopadhyay, M.; Nath, N.; Kodela, R.; Sobocki, T.; Metkar, S.; Gan, Z.Y.; Kashfi, K. Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β -catenin expression. Leuk. Res., 2013, 37, 1302-1328.
55. Kodela, R.; Chattopadhyay, M.; Kashfi, K. NOSH-aspirin: A novel nitric oxide-hydrogen sulfide-releasing hybrid: A new class of antiinflammatory pharmaceuticals. ACS Med. Chem. Lett., 2012, 3, 257-262.
56. Chattopadhyay, M.; Kodela, R.; Olson, K.R.; Kashfi, K. NOSHaspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfidereleasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Commun., 2012, 419, 523-528.
57. Kodela, R.; Chattopadhyay, M.; Kashfi, K. Synthesis and biological activity of NOSH-naproxen (AVT-219) and NOSHsulindac (AVT-18A) as potent anti-inflammatory agents with chemotherapeutic potential. Medchemcomm., 2013, 4, 1472-1481.
58. Ott, I.; Schmidt, K.; Kircher, B.; Schumacher, P.; Wiglenda, T.; Gust, R. Antitumor-active cobalt-alkyne complexes derived from acetylsalicylic acid: Studies on the mode of drug action. J. Med. Chem., 2005, 48, 622-629.
59. Rubner, G.; Bensdorf, K.; Wellner, A.; Kircher, B.; Bergemann, S.; Ott, I.; Gust, R. Synthesis and biological activities of transition metal complexes based on acetylsalicylic acid as neo-anticancer agents. J. Med. Chem., 2010, 53, 6889-6898.
60. Rubner, G.; Bensdorf, K.; Wellner, A.; Bergemann, S.; Ott, I.; Gust, R. [Cyclopentadienyl]metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents. Eur. J. Med. Chem., 2010, 45, 5157-5163.
61. O’Connor, M.; Kellett, A.; McCann, M.; Rosair, G.; McNamara, M.; Howe, O.; Creaven, B.S.; McClean, S.; Kia, A.F.; O’Shea, D.; Devereux, M. Copper(II) complexes of salicylic acid combining superoxide dismutase mimetic properties with DNA binding and cleaving capabilities display promising chemotherapeutic potential with fast acting in vitro cytotoxicity against cisplatin sensitive and resistant cancer cell lines. J. Med. Chem., 2012, 55, 1957-1968.
62. Suthar, S.K.; Sharma, N.; Lee, H.B.; Nongalleima, K.; Sharma, M. Novel dual inhibitors of nuclear factor-kappa B (NF-κB) and cyclooxygenase-2 (COX-2): Synthesis, in vitro anticancer activity and stability studies of lantadene-non steroidal anti-inflammatory drug (NSAID) conjugates. Curr. Top. Med. Chem., 2014, 14, 991-1004.
63. Suthar, S.K.; Lee, H.B.; Sharma, M. The synthesis of non steroidal anti-inflammatory drug (NSAID) - lantadene prodrugs as novel lung adenocarcinoma inhibitors via the inhibition of cyclooxygenase-2 (COX-2), cyclin D1 and TNF-α-induced NF-κB activation. RSC Adv., 2014, 4, 19283-19293.
64. Mackenzie, G.G.; Sun, Y.; Huang, L.; Xie, G.; Ouyang, N.; Gupta, R.C.; Johnson, F.; Komninou, D.; Kopelovich, L.; Rigas, B. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology, 2010, 139, 1320-1332.
65. Huang, L.; Mackenzie, G.G.; Sun, Y.; Ouyang, N.; Xie, G.; Vrankova, K.; Komninou, D.; Rigas, B. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Res., 2011, 71, 7617-7627.
66. Xie, G.; Sun, Y.; Nie, T.; Mackenzie, G.G.; Huang, L.; Kopelovich, L.; Komninou, D.; Rigas, B. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. J. Pharmacol. Exp. Ther., 2011, 337, 876-886.
67. Nie, T.; Wong, C.C.; Alston, N.; Aro, P.; Constantinides, P.P.; Rigas, B. Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo. Br. J. Pharmacol., 2012, 166, 991-1001.
68. Ouyang, N.; Ji, P.; Williams, J.L. A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon cancer in rats. Int. J. Oncol., 2013, 42, 643-650.
69. Sun, Y.; Rowehl, L.M.; Huang, L.; Mackenzie, G.G.; Vrankova, K.; Komninou, D.; Rigas, B. Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Res., 2012,14, R20.
70. Patrono, C.; Rocca, B. Nonsteroidal antiinflammatory drugs: Past, present and future. Pharmacol. Res., 2009, 59, 285-289.
71. Rayburn, E.R.; Ezell, S.J.; Zhang, R. Anti-inflammatory agents for cancer therapy. Mol. Cell. Pharmacol., 2009, 1, 29-43.
72. Arun, B.; Goss, P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol., 2004, 31, 22-29.
73. Hwang, D.H.; Fung, V.; Dannenberg, A.J. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: Role of COX-dependent and - independent mechanisms. Neoplasia, 2002, 4, 91-97.
74. Achiwa, H.; Yatabe, Y.; Hida, T.; Kuroishi, T.; Kozaki, K.; Nakamura, S.; Ogawa, M.; Sugiura, T.; Mitsudomi, T.; Takahashi, T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res., 1999, 5, 1001- 1005.
75. Sheehan, K.M.; Sheahan, K.; O’Donoghue, D.P.; MacSweeney, F.; Conroy, R.M.; Fitzgerald, D.J.; Murray, F.E. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA, 1999, 282, 1254-1257.
76. Flossmann, E.; Rothwell, P.M. British doctors aspirin trial and the UK-TIA aspirin trial. Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet, 2007, 369, 1603-1613.
77. Bardia, A.; Ebbert, J.O.; Vierkant, R.A.; Limburg, P.J.; Anderson, K.; Wang, A.H.; Olson, J.E.; Vachon, C.M.; Cerhan, J.R. Association of aspirin and nonaspirin nonsteroidal antiinflammatory drugs with cancer incidence and mortality. J. Natl. Cancer Inst., 2007, 99, 881-889.
78. Cruz-Correa, M.; Hylind, L.M.; Romans, K.E.; Booker, S.V.; Giardiello, F.M. Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology, 2002, 122, 641-645.
79. Gill, S.; Sinicrope, F.A. Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. Semin. Oncol., 2005, 32, 24-34.
80. Harris, R.E.; Chlebowskiz, R.T.; Jackson, R.D.; Frid, D.J.; Ascenseo, J.L.; Anderson, G.; Loar, A.; Rodabough, R.J.; White, E.; McTiernan, A. Breast cancer and nonsteroidal antiinflammatory drugs: Prospective results from the women’s health initiative. Cancer Res., 2003, 63, 6096-6101.
81. Calaluce, R.; Earnest, D.L.; Heddens, D.; Einspahr, J.G.; Roe, D.; Bogert, C.L.; Marshall, J.R.; Alberts, D.S. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: A randomized phase IIb trial. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 1287-1292.
82. A service of the U.S. National Institute of Health. ClinicalTrials.gov. www.clinicaltrials.gov (Accessed April 29, 2014).
83. North, G.L. Celecoxib as adjunctive therapy for treatment of colorectal cancer. Ann. Pharmacother., 2001, 35, 1638-1643.
84. Casanova, I.; Parreño, M.; Farré, L.; Guerrero, S.; Céspedes, M.V.; Pavon, M.A.; Sancho, F.J.; Marcuello, E.; Trias, M.; Mangues, R. Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. Int. J. Cancer, 2006, 118, 2381-2389.
85. Ulrich, C.M.; Bigler, J.; Potter, J.D. Non-steroidal antiinflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat. Rev. Cancer, 2006, 6, 130-140.
86. Advisory panel weighs COX-2 inhibitors’ fate. NCI Cancer Bull., 2005, 2, 1-2.
87. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Adenomatous polyp prevention on Vioxx (APPROVe) trial investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352, 1092-1102.
88. Wallace, J.L.; Viappiani, S.; Bolla, M. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol. Sci., 2009, 30, 112-117.
89. Kashfi, K. Anti-inflammatory agents as cancer therapeutics. Adv. Pharmacol., 2009, 57, 31-89.